ADVFN Logo ADVFN

No pudimos encontrar ningún resultado para:
Asegúrate de que la ortografía sea correcta o intenta ampliar tu búsqueda.

Tendencias Ahora

Listas Principales

Parece que no has iniciado sesión.
Haz clic en el botón de abajo para iniciar sesión y ver tu historial reciente.

Hot Features

Registration Strip Icon for monitor Monitoree múltiples cotizaciones en tiempo real de los principales intercambios, como la Bolsa de Valores de Londres, NASDAQ, NYSE, AMEX, Bovespa y más.
Dare Bioscience Inc

Dare Bioscience Inc (DARE)

3.34
0.11
(3.41%)
Cerrado 23 Noviembre 3:00PM
3.34
0.00
(0.00%)
Fuera de horario: 3:00PM

Herramientas de nivel profesional para inversores individuales.

Estadísticas y detalles clave

Último Precio
3.34
Postura de Compra
3.24
Postura de Venta
3.34
Volume Operado de la Acción
30,039
3.18 Rango del Día 3.42
3.05 Rango de 52 semanas 7.56
Capitalización de Mercado [m]
Precio Anterior
3.23
Precio de Apertura
3.21
Última hora de negociación
Volumen financiero
US$ 99,734
Precio Promedio Ponderado
3.3202
Volumen promedio (3 m)
42,338
Acciones en circulación
8,700,389
Rendimiento del Dividendo
-
Ratio Precio/Utilidad
-0.96
Beneficio por acción (BPA)
-3.47
turnover
2.81M
Beneficio neto
-30.16M

Acerca de Dare Bioscience Inc

Dare Bioscience Inc is a biopharmaceutical company committed to advancing innovative products for women's health. The company identifies, develops and brings to market a diverse portfolio of differentiated therapies that prioritize women's health and well-being, expand treatment options, and improve... Dare Bioscience Inc is a biopharmaceutical company committed to advancing innovative products for women's health. The company identifies, develops and brings to market a diverse portfolio of differentiated therapies that prioritize women's health and well-being, expand treatment options, and improve outcomes, primarily in the areas of contraception, fertility, and vaginal and sexual health. The company's first product, XACIATO is a single-dose vaginal gel prescription product for the treatment of bacterial vaginosis in females 12 years of age and older. The company's portfolio includes two product candidates in advanced clinical development namely, Ovaprene and Sildenafil Cream. Mostrar más

Sector
Pharmaceutical Preparations
Industria
Pharmaceutical Preparations
Sede
Wilmington, Delaware, USA
Fundado
-
Dare Bioscience Inc is listed in the Pharmaceutical Preparations sector of the NASDAQ with ticker DARE. The last closing price for Dare Bioscience was US$3.23. Over the last year, Dare Bioscience shares have traded in a share price range of US$ 3.05 to US$ 7.56.

Dare Bioscience currently has 8,700,389 shares in issue. The market capitalisation of Dare Bioscience is US$28.10 million. Dare Bioscience has a price to earnings ratio (PE ratio) of -0.96.

DARE Últimas noticias

Daré Bioscience Reports Third Quarter 2024 Financial Results and Provides Company Update

Conference Call and Webcast Today at 4:30 p.m. ET Development Program Highlights and Anticipated Milestones Ovaprene® hormone-free monthly intravaginal contraceptive candidate – pivotal Phase 3...

Daré Bioscience Announces Grant to Support Development of a Novel Non-Hormonal Contraceptive Candidate and Expansion of Ovaprene® Pivotal Study Clinical Trial Sites

- Grant funds will support activities that will aid in the identification and development of a novel non-hormonal intravaginal contraceptive product candidate. - Grant will also provide funding...

Daré Bioscience to Host Third Quarter 2024 Financial Results and Company Update Conference Call and Webcast on November 14, 2024

SAN DIEGO, Nov. 07, 2024 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ: DARE), a leader in innovation for the health and wellbeing of women, will host a conference call and live webcast at...

Daré Bioscience Selected to Receive $10 Million Award from ARPA-H’s Sprint for Women’s Health

DARE-HPV is a potential first-in-category treatment for human papillomavirus (HPV)-related cervical disease which could change the treatment paradigm for clinical HPV management. Essentially all...

Período †Variación(Ptos)Variación %AperturaPrecio MáximoPrecio MínimoAvg. Vol. diarioPrecio Promedio Ponderado
1-0.17-4.84330484333.513.5853.18511093.20578418CS
4-0.17-4.84330484333.514.63.18605803.80481704CS
12-0.23-6.442577030813.574.63.18423383.60252465CS
26-1.592-32.27899432284.9326.243.051230234.64373682CS
52-0.7256-17.84730421094.06567.563.053940614.42702491CS
156-17.06-83.627450980420.430.123.0591042417.51239995CS
260-6.26-65.20833333339.646.23.05148526719.7494669CS

Movimientos

Ver todo
  • Volumen
  • % Mayores Alzas
  • % Mayores Bajas
SímboloPrecioVol.
PDYNPalladyne AI Corporation
US$ 4.59
(129.50%)
83.07M
QMCOQuantum Corporation
US$ 9.11
(126.62%)
39.48M
NANano Labs Ltd
US$ 8.26
(89.02%)
2.03M
XCURExicure Inc
US$ 18.60
(71.27%)
4.59M
SKKSKK Holdings Limited
US$ 1.75
(59.09%)
107.47M
AMIXAutonomix Medical Inc
US$ 6.21
(-54.07%)
946.09k
CETXCemtrex Inc
US$ 0.1146
(-41.74%)
24.39M
MSWMing Shing Group Holdings Ltd
 5.90
(-35.52%)
417.08k
RMSGReal Messenger Corporation
US$ 3.09
(-26.25%)
313.51k
ENSCEnsysce Biosciences Inc
US$ 0.4414
(-25.49%)
4M
ELABElevai Labs Inc
US$ 0.0201
(-0.50%)
425.38M
NVDANVIDIA Corporation
US$ 141.95
(-3.22%)
236.51M
SMCISuper Micro Computer Inc
US$ 33.15
(11.62%)
159.61M
VRPXVirpax Pharmaceuticals Inc
US$ 0.5501
(-6.72%)
159.39M
SOUNSoundHound AI Inc
US$ 8.24
(18.05%)
107.91M

DARE Discussion

Ver más
Monksdream Monksdream 3 meses hace
DARE under $4
👍️0
powerbattles powerbattles 6 meses hace
$DARE took the starter! Secure $22 million in the non-dilutive & phase 2 and phase 3 coming $$$
👍️0
harry crumb harry crumb 7 meses hace
Wouldn’t touch this turd with monopoly money until after the r/s, an after the shorting!
👍️0
Awl416 Awl416 7 meses hace
Daré Bioscience Secures $22 Million in Non-Dilutive Strategic Royalty Financing to Advance Phase 3 First-in-Category Women’s Health Product Candidates through Key Catalysts
👍️0
willlbone willlbone 7 meses hace
Vote on R/S.
👍️0
glenn1919 glenn1919 9 meses hace
DARE.................................................https://stockcharts.com/h-sc/ui?s=DARE&p=W&b=5&g=0&id=p86431144783
👍️0
starkd748 starkd748 11 meses hace
It's dead lol
👍️0
Monksdream Monksdream 12 meses hace
DARE new 52 week low
👍️0
Monksdream Monksdream 1 año hace
DARE new 52 week low
👍️0
Monksdream Monksdream 1 año hace
DARE new 52 week low
👍️0
Monksdream Monksdream 1 año hace
DARE newb52 week low
👍️0
harry crumb harry crumb 2 años hace
Might be a runner in due time
👍️0
nonsequetor nonsequetor 2 años hace
The DARE train has not even left the station... gathering up steam...
👍️0
harry crumb harry crumb 2 años hace
1.00 average, 100k
👍️0
nonsequetor nonsequetor 2 años hace
I hope everyone loaded up Monday...
👍️0
nonsequetor nonsequetor 2 años hace
Monday, Jan 23, is the day...
👍️0
harry crumb harry crumb 2 años hace
Yep agree
👍️0
nonsequetor nonsequetor 2 años hace
If Ovaprene is approved by the FDA, it could be the first monthly non-hormonal contraceptive product for women and a first-in-category option for women seeking a hormone-free, self-administered and monthly birth control method.

https://www.biospace.com/article/releases/dare-bioscience-announces-ide-approval-for-a-single-arm-open-label-pivotal-contraceptive-efficacy-study-of-ovaprene-an-investigational-hormone-free-monthly-intravaginal-contraceptive/
👍️0
nonsequetor nonsequetor 2 años hace
DARE starts revenue soon with its first approved drug, Xaciato and its licensing partner OGN. Q1 or Q2. Milestone payments and double digit royalties.

Additionally, they have up to three products entering Ph3 trials this year: Ovaprene, Sildenafil and HRT-1. Ovaprene for sure is entering Ph3 this summer with NIH and licensing partner $BAYRY.

By 2024, they could have FDA-approved products and $4-$5B market share and exclusivity.
👍️0
nonsequetor nonsequetor 2 años hace
DARE Since Post:
$0.3266
(38.27%)
Then:$0.8534
Now:$1.18

Nice chunk of change so far...
👍️0
harry crumb harry crumb 2 años hace
Mayb, mayb not
👍️0
nonsequetor nonsequetor 2 años hace
Since my call
Jan 03, 2023 9:29 AM

$DARE It has begun...

DARE Since Post:
$0.2566
(30.07%)
Then:$0.8534
Now:$1.11

UM...AH... looks like a winner already...
and it has not even started!

BUT...

I really don't care what negativity others post. I have done my DD, bought low, and will ride the wave to prosperity.

DARE is the real thing, with one of a kind, first in class products, that will turn many heads and make some (who do their own DD) wealthy.

Good fortune to all (except shorts, who bet wrong on this leg up).
👍️0
harry crumb harry crumb 2 años hace
Could be but highly unlikely this becomes a winner
👍️0
nonsequetor nonsequetor 2 años hace
Just a little bit of DD will prove you wrong.
👍️0
harry crumb harry crumb 2 años hace
Dont count on it, this team is not an has not proven anything yet. Could use new management for a change, the stock does note promote a very good company
👍️0
nonsequetor nonsequetor 2 años hace
Hop aboard, this is just the beginning!
👍️0
nonsequetor nonsequetor 2 años hace
DARE up over 30% already this year.
👍️0
nonsequetor nonsequetor 2 años hace
Up 20% in 2 days
👍️0
nonsequetor nonsequetor 2 años hace
UP 10% since yesterday morning.
👍️0
harry crumb harry crumb 2 años hace
This pos needs to be shutdown, what a scam
👍️0
harry crumb harry crumb 2 años hace
Some more news on dare
👍️0
nonsequetor nonsequetor 2 años hace
Daré Bioscience Announces Subject Screening for Phase 2b RESPOND Study of Sildenafil Cream, 3.6% in Women with Female Sexual Arousal Disorder Complete

https://finance.yahoo.com/news/dar-bioscience-announces-subject-screening-120000980.html
👍️0
harry crumb harry crumb 2 años hace
Some news an this turd is stagnant, very boring company here
👍️0
harry crumb harry crumb 2 años hace
Looks like this pos is going to its 3 yr low of .75 area. What junk!
👍️0
nonsequetor nonsequetor 2 años hace
Q4 will be interesting
👍️0
nonsequetor nonsequetor 2 años hace
WOW!! Nice EOD catapult!!
👍️0
nonsequetor nonsequetor 2 años hace
Another week... another wait...

ZZZZZZZZZZZZZZZZZZZZZZ
👍️0
MattSav MattSav 2 años hace
Good looking week... Hope everyone is enjoying this move upwards... I know we are waiting on 4th quarter for real numbers but wondering if the sentiment here is good enough to through another 10k on shares lol
👍️0
nonsequetor nonsequetor 2 años hace
YES!
👍️0
MattSav MattSav 2 años hace
So should we be excited that they are doing Financials on a Tuesday?
👍️0
MattSav MattSav 2 años hace
So is the corporate presentation today or what I can't open the damn thing
👍️0
nonsequetor nonsequetor 2 años hace
https://www.sec.gov/Archives/edgar/data/0001401914/000149315222019342/ex3-1.htm
👍️0
MattSav MattSav 2 años hace
Anyone find out how the vote went?
👍️0
kruy kruy 2 años hace
You do realize that all the upfront payments and tiered royalties have to be split with the labs that actually invented and produce these products. DARE is only the middleman. These details are all spelled out in the last SEC annual filing.
The best thing that could happen for us shareholders is that some big company that needs a pipeline will buy out this company and its entire complicated business model. Give me $5 a share and I'm happy. Reality wise, I think we could only get $3-$4 because they would need to come to agreements with all the labs that actually engineered all of the products. Either way, I'd be happy with any buyout because the business model as is could take a long time for DARE to break even or show a profit after splitting royalties with all parties involved.
👍️0
nonsequetor nonsequetor 2 años hace
$$$$ Coming in from the Gates!
https://ih.advfn.com/stock-market/NASDAQ/dare-bioscience-DARE/stock-news/88547783/current-report-filing-8-k
👍️0
nonsequetor nonsequetor 2 años hace
This DARE stock will drive a sane man crazy!
👍️0
harry crumb harry crumb 2 años hace
Employee stock incentive plan goes into effect with dare Bod approval. Always good news to have a employee purchase plan for company stock
👍️0
MattSav MattSav 2 años hace
So im new to this stock... What are the opinions of the stock not getting its approval to increase shares?
👍️0
nonsequetor nonsequetor 2 años hace
Just a few more days...
👍️0
nonsequetor nonsequetor 2 años hace
CLINICAL TRIALS RESULTS JUST POSTED
https://www.clinicaltrials.gov/ct2/show/results/NCT03598088?view=results
👍️0

Su Consulta Reciente

Delayed Upgrade Clock